Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, ... ...

Core Viewpoint - Eli Lilly's stock is experiencing a decline due to profit-taking after a significant rally, despite strong earnings and sales performance in the fourth quarter [1][6]. Financial Performance - Eli Lilly reported fourth-quarter adjusted earnings of $7.54 per share, surpassing the consensus estimate of $6.67 [1]. - The company's sales reached $19.3 billion, exceeding the consensus of $17.96 billion [1]. - For fiscal 2026, Eli Lilly expects adjusted earnings between $33.50 and $35 per share, compared to the consensus of $33.23 [2]. Sales Projections - Eli Lilly anticipates total sales between $80 billion and $83 billion for fiscal 2026, higher than Wall Street's estimate of $77.62 billion [1]. - The topline estimate of around $82 billion for fiscal 2026 suggests incretin sales of approximately $57 billion, an increase of about $16 billion over fiscal 2025 [4]. Analyst Insights - Cantor's analyst views Eli Lilly's fiscal 2026 guidance as a strong rebuttal to concerns regarding GLP-1 pricing or demand, maintaining an Overweight rating with a price forecast increase to $1,205 from $985 [3]. - The expectation is for over 3 million orforglipron prescriptions in fiscal 2026, which is considered reasonable given various market factors [5].

来源：滚动播报 摩根大通将礼来公司的目标股价从每股1150美元上调至1300美元。 ...

Hims Stock Slides After Launching Oral Wegovy Knockoff; Novo, Lilly Tumble | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Hims & Hers Health (HIMS) launched a compounded version of Novo Nordisk's (NVO) already popular weight-loss pill on Thursday. But Hims stock reversed its early gains, while Novo and Eli Lilly (LLY) continued falling. The compounded pill will cost just $49 for the first month, roughly $100 less than what Novo Nordisk is charging for its ora ...

Market Overview - Stocks experienced a decline on Thursday, particularly in the software sector, with Big Tech companies like Alphabet and Amazon down 4.3% and 4.8% respectively, leading to a 1.4% drop in the Nasdaq and a 1% decrease in the S&P 500 [1][1][1] - The volatility in the market was described as a "clearing event" by Jim Cramer, indicating potential for continued heavy selling [1][1] Company Insights - Alphabet reported stronger-than-expected fourth-quarter earnings, showing significant growth in its cloud and Search units, but its stock fell nearly 5% due to concerns over a larger-than-expected 2026 capex guidance and profit-taking after a 65% gain in 2025 [1][1][1] - Eli Lilly's shares dropped nearly 7% following the announcement of a generic version of Novo Nordisk's Wegovy weight-loss pill by Hims & Hers, priced at $49 a month, which is $100 cheaper than Wegovy [1][1] - Despite the drop, Eli Lilly is expected to launch its own weight-loss pill, orforglipron, in the second quarter in the U.S. and internationally in 2027, which may present a buying opportunity [1][1] Additional Stocks Mentioned - Other stocks discussed included Arm Holdings, Qualcomm, and Ralph Lauren, indicating a focus on diverse sectors within the market [1]

Core Insights - The weight loss drug market is experiencing a significant divergence between Eli Lilly and Novo Nordisk, with Eli Lilly gaining market share while Novo Nordisk is facing challenges [1][2][5] Company Performance - Eli Lilly's revenue increased by 40%, with guidance for over $80 billion in revenue for the next year, significantly exceeding expectations [4] - In contrast, Novo Nordisk's stock has declined over 45% year-over-year, and they are projecting revenue declines in 2026 [2][5] Market Dynamics - Eli Lilly's GLP-1 franchise is strengthening, with their product Zepbound being the most effective on the market, which is a key driver of their performance [5][8] - The introduction of new pills in the market is attracting new customers, with 80% of users being new to the GLP-1 market [10][11] Competitive Landscape - Both companies are facing price pressures due to an intensifying price war in the weight loss drug sector [6] - Eli Lilly is expected to continue benefiting from Medicare coverage and increasing demand for its drugs [12][13] Financial Outlook - Eli Lilly is investing heavily in manufacturing, supported by strong cash flow, which is expected to reduce financial leverage over time [14] - The potential for mergers and acquisitions (M&A) poses a risk to Eli Lilly's credit metrics, although they have a conservative track record in this area [15]

Core Viewpoint - CVS Health will replace Amgen and Eli Lilly's bone disease treatments with lower-cost alternatives in its preferred drug lists starting April 1 [1] Group 1 - CVS Health is making changes to its preferred drug lists to include more cost-effective options [1] - The decision reflects a broader trend in the healthcare industry towards reducing drug costs for consumers [1]

Core Insights - Eli Lilly reported Q4 earnings that exceeded analyst expectations, with a profit of $7.54 per share on sales of $19.3 billion, compared to forecasts of $6.93 per share on $17.9 billion in sales [1] - Despite strong earnings, Eli Lilly's stock fell 6% due to competitive pressures from Hims & Hers Health, which announced a new "needle-free" GLP-1 weight loss pill [1][3] Group 1: Eli Lilly's Performance - Eli Lilly's Q4 earnings beat expectations, forecasting full-year 2026 earnings between $33.50 and $35 per share [1] - The company achieved significant sales driven by injectable GLP-1 weight loss drugs Mounjaro and Zepbound in 2025 [2] Group 2: Competitive Landscape - Hims & Hers Health introduced a compounded semaglutide pill priced at $49 for the first month, which is significantly lower than Eli Lilly's Zepbound price of $299 for the lowest-dose formulation [3][4] - Hims & Hers plans to increase the price of its GLP-1 pill to $99 per month after the introductory period, but it remains competitive compared to Novo Nordisk's pricing [4][5] - Novo Nordisk offers its injectable Wegovy at $199 and its pill form at $149, indicating a competitive pricing environment for GLP-1 drugs [4]

Feb 5 (Reuters) - Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. The company said the offering would be guided by clinical recommendations for personalized treatment, mirroring the approach it had taken with compounded injectable weight-loss drugs. Shares ​of Novo and rival Eli Lilly dropped after the launch announcement over concerns on how companies will protect margins as lower-cost alternatives emerge. Below are ...

责任编辑：张俊 SF065 责任编辑：张俊 SF065 减肥药龙头礼来（LLY）周四早盘大跌8%，该股周三大涨10.3%，因其业绩强劲并且发布了对GLP-1药 物2026年的乐观指引。 减肥药龙头礼来（LLY）周四早盘大跌8%，该股周三大涨10.3%，因其业绩强劲并且发布了对GLP-1药 物2026年的乐观指引。 ...